Physician profile
Daniel I Ross
NPI 1609876994
$3,650.26
in general payments reported to CMS, 2019-2025
35 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $182 · 2021: $575 · 2022: $475 · 2023: $565 · 2024: $753 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.02 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $432.02 | 2022-2025 | |
| Eyepoint US, INC. | $345.52 | 2021-2023 | |
| Alcon Vision LLC | $344.95 | 2019-2025 | Clareon |
| Sun Pharmaceutical Industries INC. | $267.67 | 2019-2025 | Cequa |
| Genentech USA, INC. | $229.29 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $191.08 | 2019-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $176.95 | 2019-2022 | |
| Cardinal Health 110 LLC | $150.00 | 2024 | |
| Alimera Sciences, INC. | $139.56 | 2022-2024 | Iluvien, Yutiq |
| Omeros Corporation | $123.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.56 | 2019-2022 | |
| Oyster Point Pharma, INC. | $116.43 | 2022-2025 | Tyrvaya |
| Bausch & Lomb Americas INC. | $115.57 | 2022-2025 | Xiidra, Xipere |
| Astellas Pharma US INC | $110.31 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $100.77 | 2024-2025 | Syfovre |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $94.05 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $65.84 | 2019-2022 | |
| Horizon Therapeutics Plc | $57.34 | 2021-2023 | Tepezza |
| Ani Pharmaceuticals, INC. | $57.14 | 2025 | Iluvien |
| Dompe US, INC. | $47.57 | 2025 | Oxervate |
| Lkc Technologies, INC. | $43.06 | 2025 | |
| Ocular Therapeutix, INC. | $38.22 | 2023 | Dextenza |
| Sight Sciences, INC. | $34.92 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $33.32 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
| Biotissue Holdings INC. | $31.96 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $27.04 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $26.16 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $25.15 | 2023 | Acuvue |
| Shire North American Group INC | $19.63 | 2019 | |
| Celularity INC. | $17.90 | 2021 | |
| Aerie Pharmaceuticals, INC. | $16.41 | 2021 | |
| Glaukos Corporation | $15.67 | 2022 | |
| Mallinckrodt Enterprises LLC | $14.40 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.96 | 2020 | |
| Vyera Pharmaceuticals, LLC | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.